阿德福韦酯(贺维力)治疗HBeAg阳性慢性乙型肝炎36例临床疗效观察  

The Clinical Efficacy of the Adefovir Dipivoxil in the Treatment of 36 Chronic Hepatitis B Patients with HBeAg-positive

作　　者：王艳卿[1] 卜玉杰[1] 刘翠玲[1] 曾艳丽[1] 李少昊[1] 黄凤仙[1] 张瑞霞[1] 

机构地区：[1]漯河市中心医院消化内科,漯河462000

出　　处：《临床消化病杂志》2009年第3期166-168,共3页Chinese Journal of Clinical Gastroenterology

摘　　要：目的评价阿德福韦酯(贺维力)片10mg/d治疗HBeAg阳性慢性乙型病毒性肝炎患者48周的疗效和安全性。方法入选的36例患者每日口服阿德福韦酯片10mg,每日1次,连服48周。主要疗效评估指标为血清HBV DNA的变化情况,次要疗效评估指标包括:丙氨酸转氨酶(ALT)的复常率,HBeAg阴转率和HBeAg的血清转化率。结果治疗12、24、36、48周时HBV DNA中位数水平较基线分别降低2.68log10 copies/ml、2.92log10 copies/ml、3.46log10 copies/ml、4.11log10 copies/ml;HBV DNA转阴率分别为19.44%、30.56%、45.71%、51.51%;ALT复常率分别为50%、63.89%、71.14、78.79%;HBeAg阴转率分别为2.78%、8.33%、11.43%、15.16%。结论阿德福韦酯(贺维力)10mg/d剂量治疗48周HBeAg阳性的慢性乙型病毒性肝炎患者有效、安全。Objective To evaluate the efficacy and safety of the adefovir dipivoxi] （ he weili ） 10 mg/d 48 weeks treatment in chronic hepatitis B patients with HBeAg-positive. Methods The 36 patients were treated with adefovir dipivoxil 10 mg orally once daily. The primary efficacy endpoint in this study was the log10 reduction of serum HBV DNA from baseline. Secondary endpoints were the rate of patients ALT normalization and the rate of patients with HBeAg loss and HBeAg seroconversion. Results At week 12,24,36.48,the median serum HBV DNA reduction from baseline were 2.68 log10 copies/ml,2.92 log10 copies/ml, 3.46 log10 copies/ml,4. 11 log10 copies/ml. The rate of HBV DNA undetectable were 19.44% ,30.56% ,45.71% ,51.51%. The rate of ALT normalization were 50% ,63.89% ,71.14% ,78.79%. The rate of HBeAg abolish were 2.78% ,8.33% , 11.43%, 15.16%. Conclusion Adefovir dipivoxil 10 mg once daily was safe,and effective in patients with HBeAg-positive chronic hepa- titis B.

关 键 词：慢性乙型病毒性肝炎 阿德福韦酯 HBEAG阳性 

分 类 号：R512.62[医药卫生—内科学]